COVID-19 Vaccine Safety First Year Findings in Adolescents.

ABSTRACT:

Background and objectives

The Food and Drug Administration expanded Emergency Use Authorization for use of Pfizer-BioNTech (BNT-162b2) coronavirus disease 2019 vaccine to include people ages 12 years and older on May 10, 2021. We describe adverse events observed during the first full year of the US coronavirus disease 2019 vaccination program for adolescents ages 12 to 17 years.

Methods

We conducted descriptive analyses using data from 2 complementary US vaccine safety monitoring systems: v-safe, a voluntary smartphone-based system that monitors reactions and health impacts, and the Vaccine Adverse Event Reporting System (VAERS), the national spontaneous reporting system. We reviewed reports and calculated adverse event reporting rates using vaccine administration data.

R

SUBMITTER: Hesse EM 

PROVIDER: S-EPMC10262343 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature